KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GSK) Other Gross PP&E Adjustments (2019 - 2025)

Historic Other Gross PP&E Adjustments for Gsk (GSK) over the last 7 years, with Q3 2025 value amounting to -$1.1 billion.

  • Gsk's Other Gross PP&E Adjustments rose 235.15% to -$1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 billion, marking a year-over-year increase of 235.15%. This contributed to the annual value of -$1.1 billion for FY2024, which is 721.1% up from last year.
  • Gsk's Other Gross PP&E Adjustments amounted to -$1.1 billion in Q3 2025, which was up 235.15% from -$1.1 billion recorded in Q2 2025.
  • In the past 5 years, Gsk's Other Gross PP&E Adjustments ranged from a high of -$134.2 million in Q1 2022 and a low of -$1.2 billion during Q4 2023
  • Over the past 5 years, Gsk's median Other Gross PP&E Adjustments value was -$1.0 billion (recorded in 2025), while the average stood at -$944.8 million.
  • Per our database at Business Quant, Gsk's Other Gross PP&E Adjustments soared by 8769.78% in 2022 and then plummeted by 49424.14% in 2023.
  • Over the past 5 years, Gsk's Other Gross PP&E Adjustments (Quarter) stood at -$997.5 million in 2021, then rose by 19.22% to -$805.8 million in 2022, then tumbled by 44.32% to -$1.2 billion in 2023, then grew by 6.63% to -$1.1 billion in 2024, then increased by 1.85% to -$1.1 billion in 2025.
  • Its last three reported values are -$1.1 billion in Q3 2025, -$1.1 billion for Q2 2025, and -$1.0 billion during Q1 2025.